TY - JOUR
T1 - V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients
AU - Chang, Wei Chiao
AU - Wong, Henry Sung Ching
AU - Chang, Che Mai
AU - Kao, Chih Chin
AU - Hsu, Yu Wen
AU - Liu, Xiao
AU - Chang, Wen Chang
AU - Wu, Mai Szu
N1 - Funding Information:
This work was supported by Grants from Ministry of Science and Technology, Taiwan (MY3NSC101–2320-B-038-029-MY3; MOST105-2628-B-038-001-MY4) and from Taipei Medical University, Taiwan (105TMU-CIT-02-3).
Publisher Copyright:
© 2017 The Author(s).
PY - 2017/7/11
Y1 - 2017/7/11
N2 - Background: Anemia is common among end-stage renal disease (ESRD) patients who undergone hemodialysis. The total reduction of red blood cell (RBC) count is associated with poor prognosis in these patients. Although erythropoietin (EPO) has been used as an effective treatment for ESRD patients with anemia, a large number of patients still present poor responses to EPO treatment. Methods: We measured T-cell receptor sequencing profiles, including length of complementarity-deteremining region 3 (CDR3), intra- and inter-group (EPO resistant vs. responsive) clonotype diversity, V(D)J usage profiles and V-J combinations from ESRD patients and to investigate the correlation between these features and EPO treatment efficacy. Results: Our results revealed statistical significance in the top 3 ~ 15 most abundant joint distributions of Vβ/Jβ among the two groups, suggesting the importance of V or J gene utilization in the EPO response of ESRD patients. Conclusions: In summary, we provided evidence addressing the potential correlation between the immune repertoire and EPO response in ESRD patients. Trial registration: TMU-JIRB 201309026. Registered 16 October 2013.
AB - Background: Anemia is common among end-stage renal disease (ESRD) patients who undergone hemodialysis. The total reduction of red blood cell (RBC) count is associated with poor prognosis in these patients. Although erythropoietin (EPO) has been used as an effective treatment for ESRD patients with anemia, a large number of patients still present poor responses to EPO treatment. Methods: We measured T-cell receptor sequencing profiles, including length of complementarity-deteremining region 3 (CDR3), intra- and inter-group (EPO resistant vs. responsive) clonotype diversity, V(D)J usage profiles and V-J combinations from ESRD patients and to investigate the correlation between these features and EPO treatment efficacy. Results: Our results revealed statistical significance in the top 3 ~ 15 most abundant joint distributions of Vβ/Jβ among the two groups, suggesting the importance of V or J gene utilization in the EPO response of ESRD patients. Conclusions: In summary, we provided evidence addressing the potential correlation between the immune repertoire and EPO response in ESRD patients. Trial registration: TMU-JIRB 201309026. Registered 16 October 2013.
KW - End-stage renal disease
KW - Erythropoietin treatment
KW - High-throughput sequencing
KW - T-cell receptor repertoire
UR - http://www.scopus.com/inward/record.url?scp=85022321055&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85022321055&partnerID=8YFLogxK
U2 - 10.1186/s12929-017-0349-5
DO - 10.1186/s12929-017-0349-5
M3 - Article
C2 - 28697735
AN - SCOPUS:85022321055
SN - 1021-7770
VL - 24
JO - Journal of Biomedical Science
JF - Journal of Biomedical Science
IS - 1
M1 - 43
ER -